By Sriparna Roy March 18 (Reuters) - The U.S. Food and Drug Administration has approved Johnson & Johnson's oral pill for ...

JenaValve has secured the FDA’s approval for its minimally invasive heart implant, making it the first to claim a U.S. green light to treat severe backflow through the aortic valve. | JenaValve has ...

Johnson & Johnson said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to ...

FDA approval covers adults and adolescents ≥12 years (≥88 lbs) with moderate-to-severe plaque psoriasis requiring systemic therapy or phototherapy, expanding systemic options beyond injectables.

The FDA approved icotrokinra for adults and adolescents aged 12 years and older with moderate to severe plaque psoriasis, Johnson & Johnson announced in a press release. Icotrokinra (Icotyde) is the ...

ICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance and a favorable safety profile in a once-daily pill Approval supported by four phase 3 studies that met ...

Johnson & Johnson and Protagonist Therapeutics are countering the swarm of injectable biologics that have long dominated the lucrative psoriasis market with a new approval for a much-anticipate | The ...

Merck's animal health unit got approval for a drug to treat and control certain ticks in dogs from the Food and Drug Administration. Merck said Wednesday its Bravecto Quantum is now approved to treat ...

The U.S. Food and Drug Administration on Wednesday approved Johnson & Johnson's oral pill for psoriasis, the company said.

The FDA announced a new approved use for the drug leucovorin, which Trump has touted as a treatment for autism. But the ...

Dr. Marty Makary, the FDA’s commissioner, said in a statement that the “approval represents a significant milestone for ...

The approval comes two months after Edwards Lifesciences scuttled plans to buy JenaValve for $945 million amid opposition from the Federal Trade Commission.